Skip to main navigation Skip to search Skip to main content

Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies

  • Sieun Yang
  • , Jihye Oh
  • , Soo Yeon Hwang
  • , Jihye Paik
  • , Inah Hwang

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Bruton’s tyrosine kinase (BTK) is a key signaling component downstream of the B-cell receptor (BCR) and plays an essential role in the survival and proliferation of multiple B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström macroglobulinemia (WM). BTK inhibitors (BTKi) have demonstrated substantial clinical benefit and are now widely incorporated into frontline treatment strategies. However, the long-term effectiveness of BTKi is frequently limited by the emergence of both intrinsic and acquired resistance. BTKi resistance reflects a dynamic process of cellular adaptation rather than a single dominant mechanism. Malignant B cells maintain viability under BTK inhibition through multiple, interconnected alterations, including changes in BTK structure or function, reprogramming of proximal BCR signaling, activation of alternative survival pathways, tumor microenvironment–mediated immune modulation, and metabolic and epigenetic remodeling. In this review, we summarize recent advances in BTK-targeted therapeutics and present a mechanistic framework for understanding BTKi resistance as an adaptive and context-dependent process. We discuss emerging resistance mechanisms that extend beyond canonical signaling pathways and review therapeutic strategies aimed at addressing these adaptive responses, including non-covalent BTK inhibitors, BTK degraders, and rational combination regimens. This perspective highlights translational strategies to improve the depth and durability of responses to BTK-targeted therapies.

Original languageEnglish
Article number101383
JournalDrug Resistance Updates
Volume86
DOIs
StatePublished - May 2026

Bibliographical note

Publisher Copyright:
© 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • B-cell malignancies
  • BTK inhibitor resistance
  • BTK inhibitors
  • Bruton’s tyrosine kinase

Fingerprint

Dive into the research topics of 'Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies'. Together they form a unique fingerprint.

Cite this